epilepsyfocal seizuressymptomatic focal epilepsycryptogenic focal epilepsyvalproatecarbamazepineoxcarbazepineefficacytolerabilityэпилепсияфокальные приступысимптоматическая фокальная эпилепсиякриптогенная фокальная эпилепсиявальпроаткарбамазепинокскарбазепинэффективностьпереносимость«Санофи-авентис груп»1.1. Гузева В.И. Эпилепсия и неэпилептические пароксизмальные состояния у детей. М.: МИА, 2007. С. 31–55. [Guzeva V.I. Epilepsy and non-epileptic paroxysmal states in children. Moscow: MIA, 2007. Pp. 31–55. (In Russ.)].Гузева В.И. Эпилепсия и неэпилептические пароксизмальные состояния у детей. М.: МИА, 2007. С. 31–55. [Guzeva V.I. Epilepsy and non-epileptic paroxysmal states in children. Moscow: MIA, 2007. Pp. 31–55. (In Russ.)].2.2. Карлов В.А. Эпилепсия у детей и взрослых женщин и мужчин. М.: Медицина, 2010. 720 с. [Karlov V.A. Epilepsy in children and adults, men and women. Moscow: Meditsina, 2010. 720 p. (In Russ.)].Карлов В.А. Эпилепсия у детей и взрослых женщин и мужчин. М.: Медицина, 2010. 720 с. [Karlov V.A. Epilepsy in children and adults, men and women. Moscow: Meditsina, 2010. 720 p. (In Russ.)].3.3. Мухин К.Ю., Миронов М.Б., Петрухин А.С. Эпилептические синдромы. Диагностика и терапия. 3-е изд. М.: ООО «Системные решения», 2014. С. 353–64. [Mukhin K.Yu., Mironov M.B., Petrukhin A.S. Epileptic syndromes. Diagnosis and therapy. 3rd ed., Moscow: OOO “Sistemnye resheniya”, 2014. Pp. 353–64. (In Russ.)].Мухин К.Ю., Миронов М.Б., Петрухин А.С. Эпилептические синдромы. Диагностика и терапия. 3-е изд. М.: ООО «Системные решения», 2014. С. 353–64. [Mukhin K.Yu., Mironov M.B., Petrukhin A.S. Epileptic syndromes. Diagnosis and therapy. 3rd ed., Moscow: OOO “Sistemnye resheniya”, 2014. Pp. 353–64. (In Russ.)].4.4. Мухин К.Ю., Петрухин А.С. Идиопатические формы эпилепсии: систематика, диагностика, терапия. М.: Арт-Бизнес-Центр, 2000. 320 с. [Mukhin K.Yu., Petrukhin A.S. Idiopathic forms of epilepsy: taxonomy, diagnosis, therapy. Moscow: Art-Biznes-Tsentr, 2000. 320 p. (In Russ.)].Мухин К.Ю., Петрухин А.С. Идиопатические формы эпилепсии: систематика, диагностика, терапия. М.: Арт-Бизнес-Центр, 2000. 320 с. [Mukhin K.Yu., Petrukhin A.S. Idiopathic forms of epilepsy: taxonomy, diagnosis, therapy. Moscow: Art-Biznes-Tsentr, 2000. 320 p. (In Russ.)].5.5. Мухин К.Ю., Петрухин А.С., Рыкова Е.А. Побочные эффекты антиконвульсантов при лечении идиопатической генерализованной эпилепсии. Журнал неврологии и психиатрии им. С.С. Корсакова 1997;7:25–31. [Mukhin K.Yu., Petrukhin A.S., Rykova E.A. Side effects of anticonvulsants in the treatment of idiopathic generalized epilepsy. Zhyrnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal f Neurology and Psychiatry 1997;7:25–31. (In Russ.)].Мухин К.Ю., Петрухин А.С., Рыкова Е.А. Побочные эффекты антиконвульсантов при лечении идиопатической генерализованной эпилепсии. Журнал неврологии и психиатрии им. С.С. Корсакова 1997;7:25–31. [Mukhin K.Yu., Petrukhin A.S., Rykova E.A. Side effects of anticonvulsants in the treatment of idiopathic generalized epilepsy. Zhyrnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal f Neurology and Psychiatry 1997;7:25–31. (In Russ.)].6.6. Петрухин А.С., Мухин К.Ю., Благосклонова Н.К., Алиханов А.А. Эпилептология детского возраста. М.: Медицина, 2000. С. 547–618. [Petrukhin A.S., Mukhin K.Yu., Blagosklonova N.K., Alihanov A.A. Childhood epileptology. Moscow: Meditsina, 2000. Pp. 547–618. (In Russ.)].Петрухин А.С., Мухин К.Ю., Благосклонова Н.К., Алиханов А.А. Эпилептология детского возраста. М.: Медицина, 2000. С. 547–618. [Petrukhin A.S., Mukhin K.Yu., Blagosklonova N.K., Alihanov A.A. Childhood epileptology. Moscow: Meditsina, 2000. Pp. 547–618. (In Russ.)].7.7. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic Disord 2002;4(3):217–25.Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic Disord 2002;4(3):217–25.8.8. Berg A.Т. Defining intractable epilepsy. Adv Neurol 2006;97:5–10.Berg A.Т. Defining intractable epilepsy. Adv Neurol 2006;97:5–10.9.9. Bertsche A., Neininger M.P., Dahse A.J. et al. Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness. Eur J Pediatr 2014;173(1):87–92.Bertsche A., Neininger M.P., Dahse A.J. et al. Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness. Eur J Pediatr 2014;173(1):87–92.10.10. Callaghan N., Kenny R.A., O'Neill B. et al. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985;48(7):639–44.Callaghan N., Kenny R.A., O'Neill B. et al. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985;48(7):639–44.11.11. Chadwick D., Marson T. Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients. Epilepsia 2007;48(7):1259–63.Chadwick D., Marson T. Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients. Epilepsia 2007;48(7):1259–63.12.12. de Silva M., MacArdle B., McGowan M. et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347(9003):709–13.de Silva M., MacArdle B., McGowan M. et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347(9003):709–13.13.13. Glauser T., Ben-Menachem E., Bourgeois B. et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094–120.Glauser T., Ben-Menachem E., Bourgeois B. et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094–120.14.14. Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 2006;8(2):113–29.Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 2006;8(2):113–29.15.15. Kwan P., Arzimanoglou A., Berg A.Т. et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(6):1069–77.Kwan P., Arzimanoglou A., Berg A.Т. et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(6):1069–77.16.16. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314–9.Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314–9.17.17. Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406.Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406.18.18. Motte J., Pedespan J.M., Sevestre M. et al. Acceptability and tolerance of sodium valproate, a new sustained-action granule formulation, in monotherapy for epileptic children from 3 years old. Arch Pediatr 2005;12(10):1533–9.Motte J., Pedespan J.M., Sevestre M. et al. Acceptability and tolerance of sodium valproate, a new sustained-action granule formulation, in monotherapy for epileptic children from 3 years old. Arch Pediatr 2005;12(10):1533–9.19.19. Mula M., Sander J.W. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007;30(7):555–67.Mula M., Sander J.W. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007;30(7):555–67.20.20. Nicolson A., Appleton R.E., Chadwick D.W., Smith D.F. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004;75(1):75–9.Nicolson A., Appleton R.E., Chadwick D.W., Smith D.F. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004;75(1):75–9.21.21. Panayiotopoulos C.P. A сlinical guide to epileptic syndromes and their treatment. Springer, 2007. Pр. 155–84.Panayiotopoulos C.P. A сlinical guide to epileptic syndromes and their treatment. Springer, 2007. Pр. 155–84.22.22. Panayiotopoulos C.P. Principles of therapy in the epilepsies. Springer, 2010. 100 p.Panayiotopoulos C.P. Principles of therapy in the epilepsies. Springer, 2010. 100 p.23.23. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16:695–724.Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16:695–724.24.24. Stephen L.J. Drug treatment of epilepsy in elderly people: focus on valproic аcid. Drugs Aging 2003;20(2):141–52.Stephen L.J. Drug treatment of epilepsy in elderly people: focus on valproic аcid. Drugs Aging 2003;20(2):141–52.